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ABSTRACT 
This work examines two potential mediators of cancer.  Section one considers the 
putative link between behavioral stress and cancer. We developed a stress paradigm of 
alternating established stressors that dramatically increases serum corticosterone and 
causes thymus involution. When this stress paradigm was applied to mice implanted with 
either melanoma or lymphosarcoma tumors we observed no alteration in the growth of 
either tumor.  In addition, we applied a protocol established in another laboratory that 
demonstrated a dramatic enhancement of lymphosarcoma tumors following rotational 
stress (Riley V. (1981). Psychoneuroendocrine influences on immunocompetence and 
neoplasia. Science 212, 1100-1109).  We find no significant effect on lymphosarcoma 
progression. Therefore, under the conditions used in our studies, strong behavioral stress 
does not influence tumor growth. 
 Section two considers the effects of endothelin receptor (ETR) antagonists on 
cancer progression.  Their ability to inhibit growth of many cancers is well documented, 
but similar research on glioma has been limited.  We find that two ETRB-specific 
antagonists, BQ788 and A-192621, reduce the number of viable cells in glioma and 
melanoma cell lines in a dose- and time-dependent manner.  In glioma cells, A-192621 
induces a G2/M arrest, decreases the mean number of cell divisions and enhances 
apoptosis.  BQ123, an ETRA-specific antagonist, has no effect on cell viability.  A-
192621 also up-regulates several DNA damage-inducible genes.  Interestingly, reducing 
ETRB expression with small interfering RNAs does not abrogate the effects of either A-
192621 or BQ788 in glioma or melanoma cells.  Thus, while ETRB antagonists are 
effective against glioma, it appears unlikely that their therapeutic effects are mediated by 
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ETRB.  Further investigation is needed to define the mechanism by which these 
compounds decrease cell viability.
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Section I 
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Chapter I  
Evidence for an Association Between Stress and Cancer 
 3 
Stress 
Stress activates two major neural pathways, the hypothalamic-pituitary-adrenal 
(HPA) axis and the sympathetic nervous system (SNS) (Chrousos, 1998; Moynihan, 
2003; Antoni et al., 2006) (Figure 1). Stressful stimuli are processed in the locus ceruleus 
and the hypothalamus 
by the paraventricular 
nucleus.   In the HPA 
axis, the hypothalamus 
releases corticotropin-
releasing hormone 
(CRH) and arginine 
vasopressin, which 
signal the pituitary to 
release peptides 
including cleavage 
produces of proopiomelanocortin, endorphins, enkaphalins and adrenocorticotropic 
hormone (ACTH).  ACTH then signals the adrenal cortex to release glucocorticoids 
(Figure 1).  Glucocorticoids act on various target tissues and negatively feedback on 
ACTH secretion, thereby limiting their own effects.  The SNS is stimulated by 
projections from the locus ceruleus and the paraventricular nucleus, causing the release of 
norepinephrine (NE) from the SNS and NE and epinephrine (EPI) from the adrenal 
medulla (Figure 1).  The HPA axis and the SNS also feedback on each other. 
Figure 1.  Stress activates the HPA axis and the SNS.  Figure adapted 
from Ember, 1998. 
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Signals from these pathways dictate the body’s response to stress and are 
generally considered adaptive to survive threat.  On the contrary, extended exposure to 
glucocorticoids and catecholamines can negatively affect the body.  McEwen termed the 
negative impact of stress the “allostatic load” and defined it as “the cost of chronic 
exposure to fluctuating or heightened neural or neuroendocrine response resulting from 
repeated or chronic environmental challenge that an individual reacts to as being 
particularly stressful” (McEwen & Stellar, 1993).  Allostatic load can be a result of 
frequent stress, inability to adapt to repeated, similar stressors, inability to stop 
physiologic responses once the stressor is removed, or overcompensation by one system 
when another does not respond adequately (McEwen, 1998). 
Stress has been associated with increased incidence of many diseases such as 
coronary artery disease (Ramachandruni et al., 2004), asthma (Vig et al., 2006) and 
chronic widespread pain (McBeth et al., 2007).  Psychosocial distress and life event 
stress are linked to increases in functional dyspepsia and irritable bowel syndrome (Locke 
et al., 2004; Mizuta et al., 2006).  Depression and social isolation predict mortality in 
heart failure patients (Friedmann et al., 2006).  Social stress reactivates latent herpes 
simplex virus in infected mice (Padgett et al., 1998), and examination stress reactivates 
Epstein-Barr virus in students (Glaser et al., 1999). 
 
Stress and the immune system 
 Through the activation of the HPA axis and SNS, stress affects the immune 
system.  The resulting outcome, however, is highly complex.  The age and sex of the 
subject experiencing stress as well as the intensity, duration and perception of stress all 
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influence changes in immune parameters.  In earlier work, acute stress was shown to 
increase corticosterone and depress lymphocyte stimulation and cytotoxicity in rats, 
while long-term stress enhances lymphocyte measures and corticosterone levels return to 
baseline (Monjan & Collector, 1977).  Increased circulating corticosterone can induce 
lymphocytopenia, thymus involution and loss of tissue mass from the spleen and 
peripheral lymph nodes (Keller et al., 1981; Riley, 1981). It was later demonstrated that 
stress-induced lymphocytopenia is adrenal-dependent but suppression of lymphocyte 
stimulation is independent of corticosterone (Keller et al., 1983).  Acute stress has been 
shown to both suppress and enhance immune parameters.  An acute, variable tailshock 
paradigm suppresses T-cell proliferation in both splenic and peripheral blood 
populations, while after multiple sessions, splenic T-cell responses return to baseline and 
peripheral blood responses remain suppressed (Lysle et al., 1987).  Another study using 
acute, intermittent footshock established that stress-induced suppression of lymphocyte 
proliferation and NK activity is modulated by β-endorphin but not corticosterone 
(Panerai et al., 1997).  Using a model of delayed-type hypersensitivity (DTH), acute 
stress enhanced the antigen-specific DTH response measured by ear swelling, and 
increased plasma corticosterone and leukocyte redistribution from the peripheral blood to 
the skin, while chronic stress suppressed these measures (Dhabhar & McEwen, 1996, 
1997).  Interestingly, stress did not affect the nonspecific immune response as measured 
by irritant contact sensitivity, indicating that behavioral stress affects cell-mediated 
immunity (Dhabhar & McEwen, 1996).  Adrenalectomy abolishes the acute stress-
induced leukocyte redistribution from peripheral blood and spleen to bone marrow, and 
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exogenous corticosterone administration mimics the effects of stress (Dhabhar et al., 
1996). 
Social confrontation studies using rats have demonstrated an activation of both 
the HPA axis and the SNS.  Subdominant males have decreased body mass, increased 
plasma levels of EPI and NE and while corticosterone levels are not significantly 
elevated, corticosteroid-binding capacity is decreased, thereby increasing the free, 
biologically active proportion of corticosterone (Stefanski, 2000).  Submissive and 
subdominant males have a drastically reduced number of circulating CD4+ and CD8+ 
cells and a decreased proliferative response of T-cells in blood and mesenteric lymph 
nodes (Stefanski, 1998; Stefanski & Engler, 1999).  Submissive males show an increase 
in B cells while subdominant males show either no change or a decrease.  Additionally, 
NK activity is reduced in subdominant males (Stefanski & Engler, 1999). 
Different stress exposure results in different changes in immune parameters.  
Restraint stress for 24 h increases serum corticosterone and decreases NK cell activity in 
mice and these levels recover within 48 h following release (Iwakabe et al., 1998). This 
restraint stress also decreases interferon (IFN)-γ, involved in cell-mediated immunity, but 
did not affect levels of interleukin (IL)-4, involved in humoral immunity.  This suggests a 
shift away from a T helper (Th)-1 response to a Th-2 immune response. Mice restrained 
for three hours per day for eleven days show no change in NK activity but lymphocytes 
are significantly decreased and neutrophils and large granular lymphocytes are increased 
(Steplewski & Vogel, 1986).  Following twelve days of recovery from stress, NK activity 
is enhanced, T-cells and large granular lymphocytes are increased but the percentage of 
neutrophils is below baseline. 
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 Chronic stress in humans also affects immune parameters.  In a striking 
prospective study, subjects completed a questionnaire to assess psychological stress, were 
given nose drops with either one of five respiratory viruses or saline and monitored for 
symptoms (Cohen et al., 1991).  Viral infection was confirmed by viral isolation or an 
increase in virus-specific antibodies.  Infection rates were positively correlated with the 
degree of psychological stress for all five viruses.  Later work demonstrated that people 
with higher perceived stress are at increased risk for upper respiratory infections and 
levels of cortisol, NK cell cytotoxicity and CD8+ cell numbers correlated with perceived 
stress and risk of infection while SNS markers including blood pressure, heart rate and 
catecholamine levels did not (Cohen et al., 2002).  A study of people who care for a 
spouse with progressive dementia found that this chronic stress decreases the antibody 
response and induction of IL-2 and IL-1β following influenza virus vaccination 
(KiecoltGlaser et al., 1996).  This may lead to increased vulnerability to infection.  A 
later study examining caregiver stress found both stress and age to be correlated with 
enhanced IL-10 production in CD4+ and CD8+ cells while neither affected IFN-γ or IL-2 
production in CD4+ and CD8+ cells (Glaser et al., 2001).  This suggests a shift toward 
Th-2 mediated immunity.   
The stress-induced shift from Th-1 to Th-2 mediated immunity, seen both in 
animal and human studies, plays an important role in disease resistance and progression.  
Both glucocorticoids and catecholamines promote this Th-2 shift (Elenkov, 2004).  By 
limiting the number and activity of T and NK cells, stress decreases the host’s resistance 
to many diseases.   
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Animal studies of stress and cancer 
 
There have been a number of investigations on the effects of stress on cancer 
progression in animal models.  In a mouse model of mastocytoma, inescapable shock was 
found to reduce the time to tumor appearance, enhance tumor size and decrease survival 
although these effects diminished with increased stress duration (Sklar & Anisman, 
1979).   On the contrary, escapable shock did not affect tumor growth or mortality.  A 
few years later, Riley published striking results on a mouse model of stress-induced 
cancer progression (Riley, 1981).  C3H/He mice were injected subcutaneously with 
murine 6C3HED lymphosarcoma cells on day zero.  Mice were then subjected to 
rotational stress of forty-five revolutions per minute for ten minutes out of every hour 
while in their home cage on days four, five and six.  Control animals, not subjected to the 
rotational stress, exhibited stabilized tumor growth after approximately twelve days but 
tumors in stressed mice continued to enlarge over thirty days.  Unfortunately, there were 
no error bars or statistical tests of the data, so while the results appear quite dramatic, it is 
difficult to assess the significance of the effects. 
Corticosterone plays a key role in regulating tumor growth.  Aged rats that display 
a delay in extinguishing their stress response hypersecrete corticosterone and have 
increased vulnerability to tumor growth compared to non-stressed age-matched controls, 
stressed young mice and nonstressed young mice (Sapolsky & Donnelly, 1985).  In this 
study, mice were subjected to variable stressors for one week and tumor growth was 
assessed at multiple time points.  Young, stressed mice also had increased tumor growth 
compared to age-matched controls.  A separate group of young stressed mice who were 
administered corticosterone following each stressor displayed increased tumor growth 
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over the group receiving stress alone.  Corticosterone, however, does not account for all 
stress-induced increases in tumor growth.  One interesting study tested the effects of three 
different stressors, inescapable footshock, escapable footshock and a psychological 
stressor during which mice received no footshock but heard the response of mice 
receiving inescapable footshock (Palermo-Neto et al., 2003).  Mice that experienced 
inescapable footshock or psychological stress had increased Ehrlich tumor growth as well 
as decreased macrophage spreading and phagocytosis following injection of 
Mycobacterium bovis, while mice that experienced escapable footshock were comparable 
to controls in these measures.  Interestingly, all stressed mice had elevated serum 
corticosterone indicating that other factors besides HPA axis activation are involved. 
 To assess the effect of social confrontation stress on tumor metastasis and NK 
activity, MADB 106 tumor cells were injected intravenously into rats two days after the 
start of confrontation (Stefanski & Ben-Eliyahu, 1996).  It was previously demonstrated 
that MADB106 cells selectively metastasize to the lung, and the number of metastases is 
inversely proportional to the activity of NK cells (Ben-Eliyahu et al., 1991; Ben-Eliyahu 
& Page, 1992).  Subdominant males displayed a dramatic increase in tumor burden in the 
lungs, indicating reduced NK activity.  While termed metastasis, this model only 
measures the neocolonization component of metastasis and does not address metastasis 
originating from an in situ tumor.  Another study found that the SNS mediates NK cell 
activity, thereby influencing tumor metastasis in the MADB 106 model (Shakhar & Ben-
Eliyahu, 1998).  In an experiment to mimic the effects of stress, the β-adrenergic agonist, 
metaproterenol, suppressed NK activity in a concentration-dependent manner.  This 
resulted in a 10-fold increase in the number of MADB 106 cells in the lungs after 1 day, 
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and the enhanced colonization continued for three weeks.  Nadolol, a β-adrenergic 
antagonist, blocked both metapreterenol-induced NK cell activity and increased tumor 
burden (Shakhar & Ben-Eliyahu, 1998).  Additional investigation supported these 
findings and further implicated the SNS in stress-induced tumor growth.  Swim stress 
enhanced lung colonization by MADB 106 cells and this effect was blocked by 
chlorisondamine (a ganglionic blocker), adrenal demedullation and β-adrenergic 
antagonists (Ben-Eliyahu et al., 2000).  Swim stress and adrenaline administration 
concomitantly decreased NK activity, and adrenal demedullation prevented the stress 
effect.  Pain from surgery as a stressor also enhances metastasis in this model and an 
analgesic dose of morphine blocks this effect (Page et al., 1993). 
 Stress from crowded housing and, to a lesser extent, isolated housing enhanced 
early melanoma tumor growth but this effect did not last over time (Hasegawa & Saiki, 
2002).  Social stress increased serum corticosterone and lung metastasis in a melanoma 
mouse model, while decreasing splenocyte proliferation in response to Concanavalin A 
(Vegas et al., 2006).  Another experiment with a melanoma model found that in mouse 
pairs with a stable social hierarchy, submissives had increased corticosterone and 
metastasis and decreased NK activity compared to dominant mice (Sa-Rocha et al., 
2006).  This study indicates that submissive animals experience a perpetual anxiety-like 
state since no additional stressor was administered.  In a model of ultraviolet B radiation-
induced squamous cell carcinoma, tumors appeared earlier in stressed mice, which also 
had lower serum IFN-γ and a lower number of infiltrating CD4+ cells (Saul et al., 2005). 
 In addition to modulating immune parameters, stress may more directly affect 
tumor progression.  Physiological concentrations of cortisol induced proliferation in five 
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out of ten primary cultures of metastatic breast cancer (Simon et al., 1984).  In a study of 
prostate cancer, cortisol and its metabolite, cortisone, increased tumor cell proliferation 
and prostate-specific antigen secretion by binding a mutated androgen receptor (Zhao et 
al., 2000).  Stress may also promote cancer by affecting angiogenesis and invasive 
potential.  In ovarian cancer cell lines, NE, EPI and isoproterenol, a β-adrenergic agonist, 
stimulate vascular endothelial growth factor (VEGF) production, an important stimulator 
of angiogenesis, and this effect is blocked by propranolol, a β-adrenergic antagonist 
(Lutgendorf et al., 2003).  Cortisol had mixed effects in this study, stimulating VEGF 
production in one cell line at a higher pharmacologic and stimulating VEGF production 
in another cell line at a 100-fold lower dose, while inhibiting VEGF at the higher dose.  
NE also enhanced migration of breast cancer and colon cancer cells (Masur et al., 2001; 
Drell et al., 2003).  NE increased in vitro membrane invasion of three ovarian cancer cell 
lines and this effect was blocked by propranolol (Sood et al., 2006).  In this study, NE 
enhanced matrix metalloproteinase (MMP)-2 and MMP-9 levels, key components in 
tumor invasion, and an MMP inhibitor blocked NE-enhanced tumor invasion.  EPI also 
enhanced the in vitro invasion of three ovarian cancer cell lines and cortisol increased 
invasion of one.  Interestingly, cortisol has been shown to increase the density of β-
adrenergic receptors in human lung cancer cells (Nakane et al., 1990).  This suggests that 
a stressor that increases both glucocorticoids and catecholamines would have the greatest 
impact on cancer progression. 
Recently, Thaker and colleagues demonstrated that chronic restraint stress 
enhanced ovarian tumor growth and angiogenesis in nude mice (Thaker et al., 2006).  
Restraint stress increased HeyA8 tumor weight and the number of tumor nodules in vivo 
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and this effect was mimicked with isoproterenol, a nonspecific β-adrenergic agonist, and 
terbutaline, a β2-adrenergic agonist, but not xamoterol, a β1-adrenergic agonist. 
Propranolol blocked the effects of stress and isoproterenol on tumor growth.  Mice 
injected with β-adenoreceptor-null ovarian cancer lines did not show increased tumor 
growth in response to stress.  Moreover, mice injected with HeyA8 cells in which β2-
adenoreceptor expression had been decreased with small interfering RNA also did not 
demonstrate enhanced tumor growth following stress.  In addition to growth, stress also 
induced angiogenesis and VEGF mRNA and protein levels.  Again, stress effects were 
mimicked by isoproterenol and terbutaline but not xamoterol, and were blocked by 
propranolol.  VEGF mRNA was also dramatically increased by NE administration.  
Stress also increased levels of MMP-2 and MMP-9, thereby increasing invasion potential.  
VEGF inhibitors blocked the stress-induced tumor growth indicating that VEGF and the 
neovasculature played a key role in tumor growth.   
Stress also interacts with known causes and therapies of cancer. Stress enhanced 
carcinogen action, inducing higher hepatocellular carcinoma incidence than with 
carcinogen alone (Laconi et al., 2000).  Stress reduced the effectiveness of chemotherapy 
in a mouse model of lung cancer, decreasing the proportion of long-term survivors and 
overall survival (Zorzet et al., 1998).   Dexamethasone, a synthetic glucocorticoid, 
suppresses chemotherapy-induced apoptosis in a xenograft mouse model of lung cancer, 
and in cervical carcinoma and breast cancer cell lines (Herr et al., 2003; Wu et al., 2004). 
Nonetheless, not all studies have demonstrated a correlation between stress and 
cancer.  In a melanoma mouse model, restraint stress induced changes in cytokine levels, 
decreasing IFN-γ but not IL-4, but had no effect on tumor growth (Li et al., 1997).  
 13 
Another study found that restraint stress did not consistently alter any immune parameters 
in two different strains of mice, and melanoma cells injected after stress did not show 
enhanced growth or metastasis compared to controls (Posevitz et al., 2003). 
Animal models used to investigate the effects of behavioral stress on cancer 
progression are highly complex and timing of the stressor may play a critical role.  Using 
the murine lymphosarcoma model, Riley demonstrated that injection of a synthetic 
glucocorticoid had similar effects on tumor growth as rotational stress but the 
consequence of the glucocorticoid injection was critically dependent upon its timing 
(Riley, 1981).  Given one week prior to lymphosarcoma injection, dexamethasone 
suppressed tumor growth compared to controls, while given one week after 
lymphosarcoma implantation, dexamethasone enhanced tumor growth.  Riley also 
injected slow-release depots of fluocinolone acetonide (FCA), another synthetic 
corticoid, at one, two or three weeks after lymphosarcoma implantation and found that, 
while tumor growth was enhanced above controls at all times, delayed administration of 
FCA decreased promotion of tumor growth. Increased age also positively correlated with 
increased tumor growth in the absence of any stressors.  As in Riley’s previously 
mentioned experiments, no error bars or statistics accompany the data. In another study 
of timing effects, stress was initiated before MADB 106 tumor injection and still 
increased tumor burden (Stefanski & Ben-Eliyahu, 1996).  Another factor in stress 
experimentation is housing conditions.  Increasing ventilation and reducing noise lowers 
basal corticosterone levels, and mice show an enhanced response to stress (Riley, 1981; 
Neigh et al., 2005). 
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Largely, animal studies have demonstrated that stress enhances tumor growth.  
The HPA axis and the SNS both play a role in these stress effects.  Stress promotes tumor 
progression through a variety of means including, altering immune parameters, direct 
action on tumor cell receptors, enhancing angiogenesis and increasing invasive potential. 
 
Stress and cancer in the clinic 
Proving that stress plays a role in human cancer incidence has been difficult.  
Studies have reported conflicting results when assessing if stressful life events increase 
the risk of developing cancer (Forsen, 1991; Chen et al., 1995; Protheroe et al., 1999; 
Lillberg et al., 2003; Kroenke et al., 2004). With the possible exception of death of a 
spouse, meta-analysis of the literature has not revealed a strong correlation between 
stressful life events and cancer onset (Duijts et al., 2003).  Death of a child increased the 
incidence risk of certain cancers, and it shortened survival if the death occurred after the 
cancer diagnosis in one study (Levav et al., 2000), but showed no effect on incidence risk 
in another (Kvikstad & Vatten, 1996).  Moreover, no association between stressful life 
events and cancer relapse has been demonstrated (Forsen, 1991; Kvikstad & Vatten, 
1996; Levav et al., 2000; Lillberg et al., 2003) 
Studies attempting to link patient outlook and disease progression and survival 
have yielded mixed results.  An investigation of non-small cell lung carcinoma found no 
evidence that a high level of optimism before treatment influenced progression-free 
survival or overall survival (Schofield et al., 2004). Another study of lung cancer found 
that depressive coping and emotional distress predicted shorter survival (Faller et al., 
1999).  A study of mixed cancer types found no association between optimism and 
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survival but did find a positive correlation between pessimism and mortality in younger 
patients (Schulz et al., 1996).  Unfortunately, this study did not control for the extent or 
sites of metastases, and this may have influenced the statistical analysis.  A recent study 
used the National Comprehensive Cancer Network (NCCN) Distress Thermometer to 
assess distress levels in breast cancer patients (Dabrowski et al., 2007).  The survey asked 
patients to rate their distress for the past week on a ten-point scale and then classify the 
source of the distress on a problem list with five major categories, including practical 
problems, family problems, emotional problems, spiritual or religious concerns and 
physical problems.  Of 286 patients that completed the questionnaires, 96 subjects (34%) 
reported high distress classified as five or more on the ten-point scale.  No correlation 
was found between high distress and stage of disease.  An interesting study that examined 
psychological well-being and circulating VEGF levels found that increased social support 
correlated with decreased VEGF levels, and feelings of helplessness or worthlessness 
were correlated with increased VEGF levels (Lutgendorf et al., 2002).  This could impact 
cancer neoangiogenesis.   
If stress plays a role in cancer progression, psychosocial intervention may 
alleviate stress and thereby reduce cancer occurrence or progression. One study of 
metastatic breast cancer patients found that a one-year intervention of weekly group 
therapy and self-hypnosis for pain positively correlated with overall survival (Spiegel et 
al., 1989), while a later study found no significant effects (Cunningham et al., 1998).  A 
large, multicenter investigation found that while supportive group therapy improved 
mood and pain perception in metastatic breast cancer patients, it did not correlate with 
survival (Goodwin et al., 2001).  Studies of malignant melanoma patients also 
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demonstrated a positive correlation between group therapy and immune parameters as 
well as survival and reduced recurrence (Fawzy et al., 1990; Fawzy et al., 1993).  A ten-
year follow-up found that participation in the intervention was still predictive of survival 
although the benefit had weakened from the five-to-six year follow-up (Fawzy et al., 
2003).  Presurgical psychosocial intervention showed promise in breast cancer patients 
(Larson et al., 2000).  While control patients experienced increased distress and 
decreased IFN-γ levels over time, patients who participated in the intervention 
experienced less distress and stable levels of IFN-γ.  Unfortunately, no follow-up was 
conducted to establish if psychosocial therapy had long-lasting effects on disease 
progression, recurrence or survival.  Another study of breast cancer patients undergoing 
chemotherapy found that psychological group therapy improved outlook and healthful 
behaviors and maintained baseline levels of T-cell proliferative responses, while these 
levels declined in control patients (Andersen et al., 2004).  Improved lymphocyte 
proliferation and emotional well-being was linked to cognitive-behavioral stress 
management intervention in post-surgical early-stage breast cancer patients at a three-
month follow-up (McGregor et al., 2004).  One study even found that, in healthy 
subjects, mirthful laughter while viewing a humorous video correlated with increased NK 
cell activity compared to those who viewed a tourism video (Bennett et al., 2003).  While 
many studies agree that psychosocial intervention improves patient outlook and healthy 
behaviors, it is not as clear if these and other immune-related changes result in better 
long-term outcomes.  More studies with extended follow-up are needed. 
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Modeling the effects of stress on tumor progression is complex and it is not clear 
what elicits positive results.  The work by Thaker and colleagues, previously mentioned 
in the introduction and published after the work conducted here, raises an interesting 
question regarding the role of β-adrenergic receptors in stress-induced tumor growth 
(Thaker et al., 2006).  Are β-adrenergic receptors necessary to elicit enhanced tumor 
growth following stress?  In their work, the answer is yes.  The same stress paradigm that 
increases tumor weight and nodules in cell lines that have β-adrenergic receptors has no 
effect on cell lines that are β-adrenergic receptor-null and stress effects were mimicked 
by nonspecific β-adrenergic agonist, isoproterenol, and β2-specific agonist, terbutaline, 
and blocked by nonspecific β-adrenergic antagonist propranolol.  This implicates the 
stress-induced activation of the SNS as the key component regulating stress-related tumor 
growth.  Other work has implicated the activation of the HPA by demonstrating that 
exogenous corticosterone or synthetic glucocorticoid, dexamethasone, induces tumor 
growth (Riley, 1981; Sapolsky & Donnelly, 1985).  These studies did not, however, 
investigate the role of the SNS in their models and it is possible that the glucocorticoids 
were influencing β-adrenergic receptors given the evidence that cortisol increases the 
density of β-adrenergic receptors in lung cancer (Nakane et al., 1990).  Future work 
should investigate the necessity of HPA versus SNS activation in stress-induced tumor 
growth.  This could include investigating the presence and activation of β-adrenergic 
receptors in Riley’s and Sapolsky’s exogenous glucocorticoid models as well as my 
melanoma model.  If β-adrenergic receptors are integral to stress-induced tumor growth 
then antagonists such as propranolol, already FDA approved and in common use for 
various conditions, may have therapeutic benefits.  Pending a positive effect of 
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propranolol, a non-selective β-adrenergic receptor antagonist, the scope of the 
experiments could be focused further by administering the specific β1-adrenergic 
antagonist atenolol and the specific β2-adrenergic antagonist butoxamine to determine 
through which receptor the effect was mediated (Brennan et al., 1996; Emilien & 
Maloteaux, 1998). 
Another therapy currently being investigated to combat stress-induced tumor 
growth is group therapy (Goodwin, 2005).  As discussed in the introduction, this has met 
with mixed results.  According to the literature, an animal model of stress reduction 
effects on tumor growth has never been developed.  It would be interesting to investigate 
if environmental enrichment could counteract the effects of stress on tumor growth.  
Environment enrichment is associated with decreased anxiety behavior and serum 
corticosterone levels (Fox et al., 2006).  If an animal model proved successful this would 
lend substantial credibility to human psychosocial interventions.
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Figure 1.  Biosynthesis and amino acid sequence and 
structure of endothelin-1, endothelin-2, and endothelin-
3 and related sarafotoxins. ET-2 and ET-3 differ from 
ET-1 by two and five amino acids, respectively, while 
sarafotoxin differs by seven amino acids.  Figure 
reproduced from Fagan et al., 2001. 
The endothelin system 
Endothelin (ET), later termed endothelin-1 (ET-1), is a highly potent vasoactive 
compound originally isolated and characterized in 1988 (Yanagisawa et al., 1988).  
Preproendothelin (ppET-1) is cleaved to a 39-amino acid intermediate, big-ET, that is 
then processed to mature ET by endothelin converting enzyme (ECE-1)(Figure 1).  The 
initial cleavage to proendothelin (pET-1), also known as big ET, is made by a neutral 
endopeptidase (Laporte et al., 1993) and ECE-1, a membrane-bound neutral 
metalloprotease, cleaves big ET-1 both intracellularly and extracellularly (Xu et al., 
1994).  Endothelin has regional homology to α-scorpion toxins and its vasocontrictive 
activity depends on the presence of 
extracellular calcium (Ca2+).  It was 
therefore postulated that ET-1 interacts 
directly with membrane ion channels, 
possibly the dihydropyridine-sensitive 
Ca2+ channels (Yanagisawa et al., 
1988).  Three distinct genes were soon 
identified and found to encode three 
highly similar 21-amino acid peptides, 
ET-1, ET-2 and ET-3 (Inoue et al., 
1989)(Figure 1).  Others demonstrated 
the high homology between 
endothelins and sarafotoxins, a group 
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of vasoactive and cardiotoxic peptides derived from snake venom (Kloog & Sokolovsky, 
1989)(Figure 1).  The substantially different pharmacologic profiles of these three 
peptides suggested more than one ET receptor (ETR) subtype.  Two G-protein coupled 
receptors were later identified, endothelin receptor type A (ETRA) that binds ET-1 and 
ET-2 preferentially over ET-3 (Arai et al., 1990), and endothelin receptor type B (ETRB) 
that binds all three isopeptides with equal affinity (Sakurai et al., 1990).  Binding of any 
of the ETs results in the production of inositol phosphates and increases intracellular Ca2+ 
(Sakurai et al., 1990).  In addition to vasoconstriction, ET-1 and ET-3 also exhibit 
depressor effects, inducing the release of endothelium-derived relaxing factor/nitric oxide 
(EDRF/NO) and prostacyclin in an autocrine manner through ETRB (de Nucci et al., 
1988; Emori et al., 1991a; Emori et al., 1991b; Clozel et al., 1992).  ET-1 also acts on 
other tissues, inducing atrial natriuretic peptide and thromboxane A2 secretion (Fukuda et 
al., 1988), inhibiting renin release (Rakugi et al., 1988) and stimulating aldosterone 
biosynthesis (Morishita et al., 1989).  ET-1 synthesis and secretion is stimulated by a 
variety of other compounds and processes including itself, arginine vasopressin, 
angiotensin II, catecholamines, cytokines, growth factors, hypoxia, ischemia and shear 
stress (Emori et al., 1991c; Masaki et al., 1991; Levin, 1995; Love & McMurray, 1996; 
Jougasaki et al., 2002).  ET-1 production is inhibited by nitric oxide, heparin, atrial 
natriuretic peptide, prostaglandin E2 and prostacyclin (Boulanger & Luscher, 1990; Hu et 
al., 1992; Yokokawa et al., 1993; Prins et al., 1994).  ET-1 is believed to function in an 
autocrine or paracrine mechanism and not as a circulating hormone (Wagner et al., 1992).  
Plasma ET-1 concentrations represent only a small percentage of the ET-1 production 
and clearance from circulation is very rapid (Sirvio et al., 1990; Vierhapper et al., 1990).  
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In fact, working through ETRB, the pulmonary circulation has the capacity to clear 
approximately 50% of circulating ET-1 in one pass (Dupuis et al., 1996a; Dupuis et al., 
1996b).  All three ETs and their receptors have been found in a variety of vascular and 
nonvascular tissues (Simonson & Dunn, 1990; Rubanyi & Polokoff, 1994).  While 
expression overlaps, ET-1 is found predominantly in endothelial cells, ET-2 in the 
kidneys and intestines and ET-3 in the brain (Levin, 1995).  Yet another role for ET-1 is 
that of mitogen.  ET-1 induces c-fos and c-myc expression and increases proliferation in 
vascular smooth muscle cells (Komuro et al., 1988).  A similar effect is seen in 
fibroblasts along with the production of inositol trisphosphate (IP3) and 1,2-
diacylglycerol (DAG) and the stimulation of phospholipase C (PLC) (Takuwa et al., 
1989).  ET-1 has comparable effects on other cell types such as rat glomerular mesangial 
cells (Simonson et al., 1989) and rat osteoblasts (Takuwa et al., 1990). 
 
Endothelins and development 
Endothelins are not solely important for vasoconstriction; they also play a role in 
normal development.  In a targeted mutation of the ET-1 gene, heterozygous mice appear 
normal, but, mice deficient in ET-1 die at birth from respiratory failure and have 
extensive craniofacial deformities although they exhibit no other organ abnormalities 
(Kurihara et al., 1994).  These craniofacial malformations stem from problems in the 
development of the pharyngeal arches. Other studies also support the notion that the ET 
system is involved in proper development of neural crest derivatives.  A null mutation of 
the ETRB gene in mice results in aganglionic megacolon and coat color spotting (Hosoda 
et al., 1994), a phenotype akin to hereditary syndromes in mammals including the 
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piebald-lethal mutation in mice (Lane, 1966) and Waardenburg-Shah syndrome in 
humans (Shah et al., 1981).  Hirschsprung’s disease, characterized by lack of enteric 
ganglia and failed innervation of the gastrointestinal tract, has a missense mutation in the 
ETRB gene (Puffenberger et al., 1994).  A targeted mutation of the ET-3 gene also 
produces a phenotype of megacolon and coat color spotting remarkably similar to the 
naturally occurring lethal spotting mutation in mice (Baynash et al., 1994). Using a 
tetracycline-inducible system, another study determined that ETRB is critical to neural 
crest development between embryonic days 10 and 12.5, timing important for the proper 
migration of both enteric neuroblasts and melanoblasts (Shin et al., 1999).  These data 
indicate that ET-3 signaling through ETRB is responsible for proper development of at 
least two neural crest derivatives, melanocytes and enteric ganglion neurons.  It further 
suggests that ETs do not behave like circulating hormones, since normal levels of ET-1 
and ET-2 do not compensate for the lack of ET-3.   
 
Endothelins and cancer 
The ET system has been implicated in the growth and progression of several 
cancers; its role in melanoma and glioma will be discussed in particular detail later in this 
chapter.  Many cell lines derived from cancerous tissue express and respond to 
components of the ET system.  A renal adenocarcinoma cell line was found to secrete 
immunoreactive ET-2 along with two forms of its precursor, big ET-2 (Ohkubo et al., 
1990; Onda et al., 1991; Yorimitsu et al., 1992).  In a study of five endometrial 
adenocarcinoma lines, two secreted ET-1, two had ET-1 mRNA but no detectable ET-1 
in the cultured conditioned medium and one had no evidence at all of ET-1 expression 
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(Pekonen et al., 1992).  ET-1 production and secretion has also been documented in 
mammary, pancreatic and colon carcinoma cell lines (Kusuhara et al., 1990).  Another 
group found several human carcinoma cell lines secreted ET-1 and responded to 
exogenous ET-1 with increased intracellular Ca2+ suggesting an autocrine/paracrine 
function of ET-1 in cancer (Shichiri et al., 1991a; Shichiri et al., 1991b).  Moreover, 
further investigation of two of the carcinoma lines found that ET-1 induced proliferation 
at a concentration comparable to that of circulating ET-1 in humans (Shichiri et al., 
1991b).  
Production and secretion of ET-1 and big ET-1 has also been noted in primary 
tumors.  Not surprisingly, two cases of malignant hemangionendothelioma, a tumor 
involving endothelial cells, were found to secrete ET-1 and had a concurrent rise in blood 
pressure (Yokokawa et al., 1991a, b).  In a study of hepatocellular carcinoma the 
arteriovenous difference of ET-1 and big ET-1 was measured across the tumor bed and 
increased concentrations of both were found in the venous circulation (Ishibashi et al., 
1993).  Additional histochemical analysis revealed ET-1 and big ET-1 immunoreactivity 
in tumor tissue with no positive signal in adjacent, noncancerous tissue. In ovarian cancer 
cell lines and primary and metastatic tumors, ET-1 expression and secretion is increased 
and acts in an autocrine manner through the ETRA receptor, inducing calcium signaling 
and proliferation (Bagnato et al., 1995; Bagnato et al., 1999).  Plasma ET-1 is elevated in 
metastatic prostate cancer and every prostate cancer cell line tested produces and secretes 
ET-1 (Nelson et al., 1995).  Moreover, ET-1 increases prostate cancer proliferation and 
alkaline phosphatase activity, indicating that it may be involved in bone metastasis.  
Additionally, it has been demonstrated that ET-1 enhances the mitogenic effects of other 
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known growth factors in prostate cancer and while ETRB is present in benign prostatic 
tissue, it is down-regulated in malignant tissue and mitogenic effects of ET-1 are 
mediated through ETRA (Nelson et al., 1996).  In colorectal cancer patients with and 
without metastases, plasma ET-1 is increased compared to controls, ET-1 is up-regulated, 
has a different distribution in the colon and is located in liver metastasis tumor cells but 
not normal liver cells (Shankar et al., 1998; Asham et al., 2001).  ET-1 and ETRA has 
been localized to human meningiomas and ET-1 increases proliferation through ETRA in 
tumor cells (Kitagawa et al., 1994; Pagotto et al., 1995a; Pagotto et al., 1995b).  Similar 
findings have been noted in human papillomavirus-positive cervical cancer cells (Venuti 
et al., 2000).  Increased ET-1 production has also been found in an adrenocorticotropic 
hormone-secreting bronchial carcinoid (Murakami et al., 1993), some cases of 
pheochromocytomas (Sone et al., 1991), mammary phyllodes tumors (Yamashita et al., 
1992) and other breast cancers (Yamashita et al., 1991).  ET-1 promotes survival and 
proliferation through the activation and enhancement of various signaling molecules 
including protein kinase C (PKC), epidermal growth factor (EGF), EGF receptor, insulin-
like growth factor-1 and mitogen-activated protein kinase (MAPK) (Battistini et al., 
1993; Bagnato, 1998; Pirtskhalaishvili & Nelson, 2000; Vacca et al., 2000). 
ET-1 also suppresses apoptosis, further perpetuating cancer growth.  In 
fibroblasts, apoptosis induced by serum starvation was attenuated by ET-1 at 
concentrations lower than those needed for mitogeneis (Shichiri et al., 1998).  A similar 
effect, also mediated by ETRA through MAPK, was seen in vascular smooth muscle cells 
(Shichiri et al., 2000).  Bosentan, a mixed ETRA/ETRB antagonist, enhances Fas-
mediated apoptosis in colon cancer cell lines expressing Fas and Fas ligand that are 
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generally resistant to Fas-mediated apoptosis and low doses of ET-1 blocked this effect 
(Eberl et al., 2000b).  Furthermore, BQ123, an ETRA antagonist, and 
bisindolylmaleimide IX, a PKC inhibitor, both induced apoptosis in colon carcinoma 
cells (Eberl et al., 2000a).  ET-1 also decreases apoptotic rates in melanocytes and 
melanoma cell lines that express ETRB and in a line with forced expression of ETRB 
(Eberle et al., 2002).  Additionally, BQ788, an ETRB antagonist, enhances apoptosis in 
melanoma (Lahav et al., 1999). 
Angiogenesis is another aspect of cancer progression influenced by ETs.  ET-1 
promotes proliferation, migration and invasion of human umbilical vein endothelial cells 
(HUVEC) in a dose-dependent manner and BQ788 blocked this effect (Salani et al., 
2000b).  Moreover, ET-1 enhanced vascular-like cord formation on Matrigel and 
augmented vascular endothelial growth factor (VEGF)-induced angiogenesis in vivo.  In 
rat corneas, ET-1 and ET-3 induce angiogenesis through ETRA activation in a higher 
percentage of animals than VEGF (Bek & McMillen, 2000).  In ovarian tumors, ET-1 
expression has been correlated with VEGF expression and neovascularization (Salani et 
al., 2000a).  Additionally, ET-1 increased VEGF production through ETRA activation in 
an ovarian cancer cell line.  A separate study of ovarian cancer cell lines also found that 
ET-1 increased VEGF mRNA and protein levels, enhanced hypoxia inducible factor 
(HIF)-1α stabilization and activated the HIF-1 transcription complex in an ETRA-
mediated manner, all factors that promote angiogenesis (Spinella et al., 2002). 
In addition to effects on growth and angiogenesis, ETs may also promote tumor 
invasion.  In ovarian cancer cell lines, ET-1 induces the secretion and activation of 
several tumor proteinases through binding ETRA, thereby promoting their migration and 
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invasive capabilities measured by matrix metalloproteinase (MMP)-dependent invasion 
through Matrigel (Rosano et al., 2001; Rosano et al., 2002). 
 
Endothelin receptor antagonists 
 Due to the role of the ETs in several disease processes, a wide range of ETR 
antagonists have been developed including peptides and now more recently bioavailable 
small molecules.  The first ETR antagonist was identified a mere two years after ETs 
were first characterized although this compound, [D-Arg1,D-Phe5,D-Trp7,9,Leu11] 
substance P, is actually a nonspecific neuropeptide antagonist that also blocks the effects 
of bombesin, vasopressin and bradykinin (Fabregat & Rozengurt, 1990).  Because of the 
ETRB’s role in clearance of ET-1 from circulation, administration of ETRB antagonists 
and ETRA/ETRB nonselective antagonists increase plasma ET-1 (Donckier et al., 1995; 
Dupuis et al., 1996a; Hemsen et al., 1996; Reinhart et al., 2002).  Interestingly, while 
ETRA is not known to be involved in ET-1 clearance from circulation and ETRA 
antagonists generally do not affect plasma ET-1 levels there has been one case where 
circulating ET-1 has decreased after administration of sitaxsentan, a specific ETRA 
antagonist (Givertz et al., 2000).  While the mechanism for this ETRA antagonist-
induced decrease in plasma ET-1 is not known, it was postulated that ET-1 production 
may have decreased or the antagonist may have displaced ET-1 from ETRA to ETRB for 
clearance.  Another study demonstrated an increase in plasma ET-1 following 
administration of Atrasentan, an ETRA specific antagonist, from an unknown mechanism 
(Verhaar et al., 2000).  ETR antagonists have been most thoroughly studied in treatment 
of cardiovascular diseases.  In fact, several drugs are in clinical trials and Bosentan (trade 
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name, Tracleer®), a dual ETRA/ETRB antagonist, was approved by the U.S. Food and 
Drug Administration (FDA) for treatment of pulmonary arterial hypertension in 2001 
(Table 1).  While ETR antagonists are generally well tolerated, side effects do occur.  
Most side effects reported appear to be related to nonspecific vasodilating effects and 
include headache, dizziness, chest pain, fatigue, nasal congestion, flushing and peripheral 
edema (Barst et al., 2002; Luscher et al., 2002; Rubin et al., 2002; Anand et al., 2004; 
Dingemanse & van Giersbergen, 2004).  These effects were generally not significantly 
different from placebo-treated control groups.  One side effect that did differ between 
treatment groups was concentration-dependent liver toxicity, which was generally 
reversible upon drug discontinuation (Channick et al., 2001; Rubin et al., 2002; 
Dingemanse & van Giersbergen, 2004).  This toxicity appears to be a result of impaired 
bile salt transport leading to bile salt accumulation and increases in liver enzyme levels 
(Fattinger et al., 2001; Fouassier et al., 2002).  ETR antagonists are also being studied as 
possible therapeutics for cancer.  Effects of ETR antagonists include blocking ET-1-
induced mitogenesis, inhibiting tumor growth in vitro and in vivo, promoting apoptosis, 
decreasing tumor proteinases to inhibit invasion, decreasing angiogenesis and enhancing 
other chemotherapeutic agents (Table 2).  The role of ETR antagonists in melanoma and 
glioma is discussed in further detail in their respective sections. 
 
Endothelins and melanoma 
In accord with the previously mentioned role ETs play in neural crest 
development, ET-1 and ET-3 induce proliferation of neural crest cells and promote their 
differentiation into mature, pigmented melanocytes (Lahav et al., 1996; Reid et al., 
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1996).  Links between ETs and developing melanocytes naturally led to the investigation 
of the ET system in melanoma since malignant cells resemble progenitors in their high 
proliferation rate, high motility, low degree of differentiation or lack of contact 
inhibition.  In melanoma cell lines, ET-1, ET-3 and ETRB are all functionally expressed 
and binding of ET-1 or ET-3 to ETRB increases proliferation (Yohn et al., 1994; Kikuchi 
et al., 1996). ET-1 also reduces basal apoptotic levels in melanoma cell lines expressing 
ETRB (Eberle et al., 2002).  On the contrary, one study found that ET-1 inhibited growth 
and induced apoptosis in synchronized A375 human melanoma cells (Okazawa et al., 
1998).   
ET-1 is also produced by human keratinocytes, cells that surround melanocytes in 
situ, and its secretion is enhanced in a concentration-dependent manner following 
ultraviolet B (UVB) irradiation (Imokawa et al., 1992).  In human skin, UVB appears to 
stimulate ET-1 and ETRB expression via stem cell factor (SCF).  UVB irradiation 
enhanced SCF expression after 3 days and ET-1 and ETRB expression after 5-10 days, 
and exogenous SCF application to cultured human melanocytes increased ETRB 
expression and ET-1 binding (Hachiya et al., 2004).  Moreover, melanocytes exposed to 
ET-1 following UVB were able to overcome the UVB-induced G1 growth arrest (Tada et 
al., 1998).  Through paracrine signaling, ET-1 could promote melanoma development 
following sunburn.  ETs role in transforming melanocytes to melanoma was further 
supported using a skin graft model (Berking et al., 2004).  Using newborn human skin 
grafts on severe combined immunodeficient mice, combination treatment of SCF, basic 
fibroblast growth factor, and ET-3 caused clustering of melanocytes and migration in the 
upper layers of the epidermis and the epidermo-dermal junction.  Individually, the growth 
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factors had no effect.  Addition of UVB irradiation to the combined growth factor 
treatment resulted in pigmented lesions, in situ and invasive melanomas capable of 
forming colonies in soft agar.  Using adult human skin grafts, in situ melanomas formed 
with the treatment of combined growth factor independent of UVB irradiation although 
the melanomas were less severe and noninvasive.  All lesions regressed upon removal of 
growth factors and colonies on soft agar also required growth factor supplementation and 
displayed a finite life span.  It was postulated that additional factors or time of stimulation 
might be required to induce stable alterations allowing for autonomous growth. 
ETRA expression is inversely correlated with degree of malignancy but ETRB 
expression patterns are not as clear.  In one study, cell lines derived from primary 
melanoma had a more robust growth response to ET-1 and higher ETRB mRNA 
expression than those cell lines derived from metastatic melanoma (Kikuchi et al., 1996).  
Correlating evidence demonstrated that ETRB was down-regulated in melanoma cell 
lines compared to normal melanocytes and pigment genes for tyrosinase correlated 
positively with ETRB and negatively with ETRA (Eberle et al., 1999).  Tyrosinase genes, 
TRP-1 and TRP-2, were previously demonstrated to be down-regulated in melanoma cell 
lines compared to melanocytes (Eberle et al., 1995).  On the contrary, a study examining 
nevi and malignant melanoma lesions found increased ETRB expression in malignant 
and metastatic melanomas over common and dysplastic nevi and ETRB expression 
correlated positively with the level of invasion in malignant lesions (Demunter et al., 
2001).  Interestingly, forced differentiation of melanoma cell line A375 resulted in 
induction of ETRA while, untreated, this cell line expresses ETRB nearly exclusively 
(Ohtani et al., 1997).  
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Our laboratory previously demonstrated that the ETRB-specific antagonist, 
BQ788, inhibits melanoma cell growth and induces apoptosis both in vitro and in a 
xenograft mouse model (Lahav et al., 1999).  In vitro, BQ788 reduced the number of 
viable cells in several human melanoma cell lines in a dose-dependent manner but had no 
effect on a human kidney cell line.  BQ123, an ETRA-specific antagonist, had no effect 
on cell number despite ETRA expression.  BQ788 also induced phenotypic changes in 
some melanoma cell lines, enhancing pigmentation and dendritic outgrowth, and 
resembling differentiated melanocytes.  BQ788 also induced apoptosis in some 
melanoma cell lines measured by terminal deoxynucleotidyltransferase-mediated UTP 
nick-end labeling (TUNEL).  Additionally, sarafotoxin 6c, an ETRB-specific agonist, 
blocked the effects of BQ788 on cell number.  Both intratumor and systemic injection of 
BQ788 inhibited the growth of A375 cells in nude mice.  Moreover, BQ788 
administration resulted in tumor regression in half of the mice treated systemically.  
Increased TUNEL staining in the excised tumors treated with BQ788 indicated induction 
of apoptosis. 
Application of bosentan to five primary cultures of melanoma cells decreased 
viable cell number by inhibiting DNA synthesis and inducing apoptosis (Berger et al., 
2006).  While all cultures displayed decreased DNA synthesis, one derived from a 
primary melanoma did not show a significant reduction in cell number.  Two cultures, 
one from a primary melanoma and another from a lymph node metastasis, did not display 
increased apoptosis although two different cultures from primary melanoma and lymph 
node metastasis did, indicating that this response was not a function of the degree of 
malignancy.  Binding studies using BQ123 and BQ788 determined that ET-1 binding is 
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mediated through ETRB although exogenous ET-1 did not induce proliferation in this 
case.  Bosentan application also displayed additive effects in reducing cell number when 
combined with dacarbazine, an alkylating agent, in a line derived from a cutaneous 
metastasis. 
Another study using primary cultures of melanoma derived from various stages of 
disease found that BQ788 was most effective at reducing cell number in a lymph node 
metastasis compared to a cutaneous metastasis or a primary lesion (Lahav et al., 2004).  
BQ788 reduced expression of anti-apoptotic factor, BCL-2A1, DNA repair enzyme, 
poly(ADP-ribose) polymerase 3 (PARP-3), and ETRB in metastatic melanomas after two 
days of treatment and increased apoptosis after five days of treatment.  The primary 
melanoma culture did not display these responses to BQ788.  Thus, reduction of BCL-
2A1 and PARP-3 expression paralleled reduction in cell numbers.  A pan-caspase 
inhibitor and a caspase-6 inhibitor blocked the apoptotic effects of BQ788, supporting 
BQ788 induction of caspase-mediated apoptosis.  Reduction of ETRB by small 
interfering RNA (siRNA) reduced cell viability in metastatic melanoma.  This effect was 
positively correlated with degree of malignancy. 
An additional function of ET-1 and ET-3 is to down-regulate mRNA and protein 
levels of E-cadherin as well as α- and β-catenins (Jamal & Schneider, 2002; Rosano et 
al., 2004b).  Furthermore, ET-1 and ET-3 lead to a gain of N-cadherin and induce 
integrin expression and activation of MMP-2, MMP-9, membrane type-1-MMP, and 
tissue inhibitor MMP-2 leading to increased cell motility and invasion (Bagnato et al., 
2004).  It had been previously shown that there is a switch from E-cadherin to N-cadherin 
expression during melanoma development and forced E-cadherin expression by 
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melanoma cells leads to cell adhesion with keratinocytes, restoring the normal regulatory 
dominance of keratinocytes and inhibiting invasion of melanoma cells (Hsu et al., 2000a; 
Hsu et al., 2000b).  Further work found that ET-1 and ET-3, functioning through ETRB, 
also signal HIF-1α and cyclooxygenase (COX) to promote melanoma invasiveness 
(Spinella et al., 2007).  Under normoxic conditions, ET-1 and ET-3 stimulate VEGF, 
HIF-1α, prostaglandin E2 (PGE2), COX-1 and -2 expression, and COX-2 promoter 
activity.  Hypoxic conditions amplified this effect.  COX-1/-2 inhibitors blocked ET-1 
induction of VEGF and PGE2 secretion as well as MMP activation and cell invasion 
capabilities.  Reducing ETRB expression with siRNA and inhibiting ETRB activation 
with BQ788 individually blocked ET-induced effects.  Reduction of HIF-1α by siRNA 
also attenuated ET-3 induction of VEGF, PGE2, COX activity and MMP activation.  This 
indicates that ETs play a role in the survival and growth of melanoma as well as the 
interactions involved in disease progression. 
Mutations in ETRB may also play a role in melanoma development.  
Nonsynonymous variants of ETRB have been linked to an increased risk for malignant 
melanoma (Soufir et al., 2005).  Nonetheless, a separate investigation that focused on 
only one of the more common ETRB variants, but which screened a larger patient pool, 
failed to find a correlation to melanoma risk (Thirumaran et al., 2006). 
 
Endothelins and glioma 
Shortly after ETs had been identified, it was established that while ET-1 does not 
cross the blood-brain barrier (Koseki et al., 1989), it is located in the brain (Lee et al., 
1990), spinal cord neurons and dorsal root ganglia (Giaid et al., 1989) and nonvascular 
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binding sites were identified (Jones et al., 1989; Koseki et al., 1989; Kurihara et al., 
1990; Kohzuki et al., 1991).  ET-3 was also localized to the brain (Shinmi et al., 1989). 
ET-1 and ET-3 binding sites have similar distribution throughout the brain (Nambi et al., 
1990).  It was subsequently suggested that in addition to its other roles, ET-1 might act as 
a neurotransmitter or neuromodulator (Giaid et al., 1989; Jones et al., 1989; Koseki et al., 
1989; Yanagisawa & Masaki, 1989; Lee et al., 1990; Kohzuki et al., 1991).  ETRA and 
ETRB are differentially expressed throughout the body and ETRB is the predominant 
receptor type in nonvascular neural tissue (Williams et al., 1991; Hori et al., 1992; 
Fernandez-Durango et al., 1994).   
Considerably less has been studied about ET’s role in glioma progression 
compared to other cancers.  It is known that human glioblastoma and neuroblastoma cell 
lines express ETRA and ETRB (Takahashi et al., 2002) and produce and secrete ET-1 
(Hamroun et al., 2000; Sone et al., 2000; Takahashi et al., 2002).  Glioblastoma cell lines 
also express ppET-1, ppET-3 and ECE-1, in addition to ETRA and ETRB (Egidy et al., 
2000).  Another investigation examined one low grade human astrocytoma cell line and 
eight human glioblastoma cell lines (Paolillo et al., 2006).  This work detected ppET-1 
and ETRB mRNA in all nine lines but ppET-1 and ETRA were only found in the 
astrocytoma cells and four of the glioblastoma lines.  In four of the five cell lines that 
coexpressed ETRA and ETRB, ETRB mRNA levels were approximately 3.5 times higher 
than ETRA.  The ppET-1 mRNA levels correlated extremely well with the levels of 
secreted ET-1 and exogenous ET-1 induced ERK phosphorylation (Paolillo et al., 2006).   
In a neuroblastoma cell line, ET-1, binding ETRA, induces an increase in intracellular 
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Ca2+ and inositol phosphate and inhibits cyclic adenosine monophosphate (cAMP) 
formation (Heinroth-Hoffmann et al., 1998).  
Several human glioma surgical specimens have also demonstrated ET-1 
immunoreactivity with a positive correlation to degree of malignancy (Stiles et al., 1997).  
Another study found glioblastoma multiforme tumors express ETRA on the 
neovasculature and ETRB on nonvascular, tumor cells (Harland et al., 1998).  ET-1, 
ECE-1, ETRA and ETRB have also all been detected in several human astrocytoma 
specimens (Naidoo et al., 2005).  Surgical samples of oligodendrogliomas, 
oligoastrocytomas, and glioblastomas also displayed ETRB immunoreactivity 
(Anguelova et al., 2005).  Interestingly, the oligodendroglioma and oligoastrocytoma 
samples were varied in the location of ETRB, some had nuclear staining, some had 
cytoplasmic and others had both, although the astrocytic component of the 
oligoastrocytomas only stained cytoplasmically.  In the glioblastoma specimens, ETRB 
was present in the cytoplasm in limited cells.  Neovasculature was postitive for ETRB in 
oligodendrogliomas and oligoastrocytomas but negative for ETRB in glioblastomas.  
ETRA immunoreactivity was only found in some glioblastoma cells and control neurons.  
In primary cultures of oligodendrogliomas, ET-1 induced the transient phosphorylation of 
ERK and focal adhesion kinase indicating that ETRB was functionally coupled to 
mitogenic pathways.  BQ788 administration induced cytotoxicity and severe 
morphological changes associated with cytoplasmic vacuoles while BQ123 had no effect 
on the cells.  ETRB-positive reactive astrocytes were also found in surrounding tissue.  
This is not surprising given previous evidence that reactive gliosis occurs around brain 
metastases and involves an up-regulation of ET immunoreactivity and secretion of ET-1 
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(Zhang & Olsson, 1995, 1997).  One study took another approach to disrupting ET 
signaling by targeting ECE-1 (Berger et al., 2005).  Using small molecule inhibitors of 
ECE-1, they were able to inhibit DNA synthesis in human glioblastoma cells.  
Application of exogenous big ET-1 and, interestingly, ET-1 could not overcome the 
growth inhibition.  These ECE-1 inhibitors, therefore, block proliferation through a 
mechanism independent of extracellular ET-1 production. 
Bosentan administration induced apoptosis in four glioblastoma cell lines in a 
dose-dependent manner but ET-1 did not stimulate proliferation despite transiently 
phosphorylating p44/42 MAPK/extracellular signal-regulated kinase (ERK), a known 
step in proliferation induction (Egidy et al., 2000).  Recently, it has been demonstrated 
that ET-1 induced proliferation in astrocytoma cells involves the MAPK-, PKC- and 
phosphoinositide 3-kinase (PI3K)-dependent pathways (He et al., 2007).  Interestingly, 
these pathways did not demonstrate any “cross talk” as a both a PKC inhibitor and a 
PI3K inhibitor independently attenuated proliferation but had no effect on ERK 
phosphorylation.  BQ788, however, did block ERK phosphorylation while BQ610, an 
ETRA-specific antagonist, had no effect.  Another molecule receiving attention in 
glioblastoma is HIF-1. In hypoxic tumor areas, HIF-1 is stabilized and activated in 
glioblastoma leading to neoangiogenesis (Kaur et al., 2005).  As previously mentioned, 
ET-1 stabilizes HIF-1α and activates the HIF-1 transcriptional complex in ovarian cancer 
(Spinella et al., 2002). It is also known that, conversely, HIF-1 can induce ET-1 (Hu et 
al., 1998).  These molecules can thereby function in a positive feedback loop promoting 
the growth of glioblastoma.  Together, these data demonstrate a potential role of ETs in 
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regulating glioma progression and highlight the need for further investigation of the 
pathways by which the act in this type of cancer. 
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Table 1.  Endothelin receptor antagonists in clinical trials 
 
Name Target Disease Comments 
ETRA/ 
 ETRB 
Pulmonary arterial 
hypertension 
FDA approved  
(Motte et al., 2006) 
   
Bosentan 
(Tracleer®) 
(RO 47-0203) 
(Clozel et al., 
1994) 
 Systemic sclerosis 
• Digital ulcers 
• Raynaud’s 
phenomenon 
• Myocardial 
perfusion and 
function 
Clinical improvement noted 
(Korn et al., 2004; Allanore et 
al., 2006; Moore et al., 2007) 
    
  Metastatic 
melanoma 
Disease stabilization in some 
patients (Kefford et al., 2006) 
    
Enrasentan  
(SB-217242) 
(Ohlstein et al., 
1996) 
ETRA/ 
 ETRB 
Congestive heart 
failure 
No clinical benefit 
(Louis et al., 2001) 
    
Acute heart failure 
 
Mixed results (Cotter et al., 
2004) 
  
Tezosentan 
(Veletri™) 
(RO 61-0612) 
(Clozel et al., 
1999) 
ETRA/ 
 ETRB 
Hepatorenal 
syndrome 
Clinical study ongoing 
(Motte et al., 2006) 
    
Ambrisentan 
(LU-209075) 
(Billman, 2002) 
ETRA Pulmonary arterial 
hypertension 
Clinical improvement noted 
(Galie et al., 2005) 
    
Atrasentan 
(Xinlay™)  
(ABT-627) 
(Opgenorth et al., 
1996; Winn et al., 
1996) 
ETRA Prostate cancer Delayed progression and 
improved quality of life (Fisher, 
2002; Carducci et al., 2003; 
Michaelson et al., 2006) 
    
Clazosentan 
(RO 61-7790) 
(Roux et al., 1997) 
ETRA Subarachnoid 
hemorrhage 
Phase IIa looked promising 
(Vajkoczy et al., 2005), in 
phase IIb (Motte et al., 2006) 
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Name Target Disease Comments 
Systemic 
hypertension 
Promising outcomes (Nakov et 
al., 2002) 
  
Darusentan 
(LU-135252) 
(Raschack et al., 
1995) 
ETRA 
Chronic heart 
failure 
Mixed outcomes (Anand et al., 
2004; Bergler-Klein et al., 
2004) 
    
Edonentan 
(BMS-207940) 
(Hulpke-Wette & 
Buchhorn, 2002) 
ETRA Congestive heart 
failure 
Entered phase I trials  
(Hulpke-Wette & Buchhorn, 
2002) 
    
Sitaxsentan 
(Thelin™) 
(TBC-11251) (Wu 
et al., 1997) 
ETRA Pulmonary arterial 
hypertension 
Clinical improvements noted 
(Barst et al., 2004; Barst et al., 
2006) 
    
Entered phase I trials 
(Motte et al., 2006) 
TBC-3711 
(Wu et al., 2004) 
ETRA Pulmonary arterial 
hypertension & 
cardiovascular 
diseases 
 
    
YM598  
(Yuyama et al., 
2003) 
ETRA Prostate cancer Entered phase I trials 
(Nelson et al., 2003) 
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Table 2. Select endothelin receptor antagonists in the treatment of 
cancer 
 
Name Target Cancer Effect 
A-127722 ETRA Prostate Inhibits ET-1 stimulated growth  
(Nelson et al., 1996) 
    
BQ610 ETRA Glioblastoma Decreases cell number (Takahashi et al., 2002) 
    
ETRA Cervical Inhibits basal growth rate and ET-1 stimulated 
growth (Venuti et al., 2002)  
Inhibits growth and neoangiogenesis in 
xenografts, additive effects with paclitaxel 
(Bagnato et al., 2002) 
   
Atrasentan 
(ABT-627) 
 Ovarian Inhibits ET-1 stimulated growth  
(Salani et al., 2002) 
Inhibits xenograft tumor growth, enhances 
cytotoxic agents (Rosano et al., 2004a) 
    
  Prostate In clinical trials (Table 1) 
    
ETRA Meningioma Inhibits ET-1 stimulated growth (Pagotto et al., 
1995a) 
   
 Cervical Inhibits growth in culture (Venuti et al., 2000) 
   
BQ123 
(Ihara et 
al., 1992) 
 Colorectal Decreases liver metastasis tumor weight in rats 
(Asham et al., 2001) 
    
  Ovarian Inhibits ET-1 induced increase in tumor 
proteinase activity, decreases migration and 
invasive potential  
(Rosano et al., 2001; Rosano et al., 2002) 
    
Bosentan ETRA
/ETRB 
Metastatic 
melanoma 
In clinical trials (Table 1) 
    
  Melanoma Decreases cell viability and DNA synthesis, 
induces apoptosis, additive effects to alkylating 
agents (Berger et al., 2006) 
    
  Glioblastoma Induces apoptosis (Egidy et al., 2000) 
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Name Target Cancer Effect 
BQ788 
(Ishikawa 
et al., 
1994) 
ETRB Melanoma Inhibits growth in culture, inhibits xenograft 
tumor growth, induces apoptosis  
(Lahav et al., 1999) 
Blocks activation of MMPs (Bagnato et al., 2004) 
    
  Astrocytoma Inhibits ERK phosphorylation (He et al., 2007) 
    
  Oligodendro-
glioma 
Induces cytotoxicity and morphological changes 
(Anguelova et al., 2005) 
    
A-192621 
(von 
Geldern et 
al., 1999) 
ETRB Melanoma Inhibits xenograft tumor growth  
(Bagnato et al., 2004; Rosano et al., 2004b) 
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Chapter V  
Endothelin Receptor B Antagonists Decrease Glioma Viability 
Independently of Their Cognate Receptor 
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Abstract 
Endothelin receptor antagonists inhibit the progression of many cancers, but 
research into their influence on glioma has been limited.  We report that two endothelin 
receptor type B (ETRB)-specific antagonists, A-192621 and BQ788, reduce the number 
of viable cells in two glioma cell lines in a dose- and time-dependent manner.  We 
describe similar results for two melanoma cell lines. The more potent of the two 
antagonists, A-192621, decreases the mean number of cell divisions at least in part by 
inducing a G2/M arrest and apoptosis.  Microarray analysis of the effects of A-192621 
treatment reveals up-regulation of several DNA damage-inducible genes.  These results 
were confirmed by real-time RT-PCR.  Importantly, reducing expression of ETRB with 
small interfering RNAs does not abrogate the effects of either A-192621 or BQ788 in 
glioma or melanoma cells.  Furthermore, BQ123, an endothelin receptor type A-specific 
antagonist, has no effect on cell viability in any of these cell lines, suggesting that the 
ETRB-independent effects on cell viability exhibited by A-192621 and BQ788 are not a 
result of ETRA inhibition. Thus, while ETRB antagonists reduce the viability of glioma 
cells, it appears unlikely that their therapeutic effects are mediated via ETRB inhibition 
or cross-reaction with ETRA. 
 
Introduction 
 The endothelin (ET) family includes three 21-amino acid peptides, ET-1, ET-2 
and ET-3, which bind to two G-protein-coupled receptors, endothelin receptor type A 
(ETRA) and endothelin receptor type B (ETRB).  The ETRA binds ET-1 and ET-2 with 
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equal preference over ET-3, while ETRB binds all three isoforms with equal affinity (1).  
The ET axis is believed to play a role in various malignancies including ovarian, prostate, 
cervical and breast carcinomas, melanoma and central nervous system tumors (2).  The 
influence of the ET family on cancer is multifactorial:  ET-1 induces proliferation (3-7), 
suppresses apoptosis (8), enhances angiogenesis (9, 10) and promotes invasion (11-13). 
 Components of the ET system have been found in many glioma tumor specimens 
and cell lines, and ET expression positively correlates with the degree of malignancy (14-
17).  Two studies demonstrated ETRA on the neovasculature of glioblastoma tumors, 
while ETRB was localized to the tumor cells (18, 19).  Inhibitors of endothelin 
converting enzyme 1, which converts ET-1 into the active form, block DNA synthesis in 
glioblastoma cells (20).  ET-1 induces proliferation in glioblastomas through various 
pathways including the mitogen-activated protein kinase (MAPK) pathway, and BQ788, 
an ETRB-specific receptor antagonist, blocks the phosphorylation of extracellular signal-
related kinase, a key step in MAPK signaling (21).  This led us to consider whether 
potential therapeutic candidates, the ETRB antagonists, negatively impact glioma growth. 
Our laboratory previously showed that high doses of BQ788 inhibit melanoma 
proliferation both in vitro and in vivo (22). We are currently investigating the effects of 
ETRB antagonists on melanoma and glioma, with particular interest in two ETRB-
specific antagonists, BQ788, a peptide, and A-192621, an orally bio-available small 
molecule.  In the present work we demonstrate that both ETRB antagonists decrease the 
number of viable cells in melanoma and glioma cultures, while an ETRA-specific 
antagonist, BQ123, has no effect.  In glioma cells, A-192621 induces cell cycle arrest, 
apoptosis and expression of DNA-damage associated genes.  Importantly, the presence of 
 103 
ETRB appears to not be required for the reduction in cell number by either ETRB 
antagonist.  
 
Materials and Methods 
Cells and cell culture conditions.  The human glioma cell lines LN-229 and 
SW1088 and the human melanoma cell line A375 (American Type Culture Collection 
(ATCC), Manassas, VA, USA) were maintained in Dulbecco’s Modification of Eagle’s 
Medium (DMEM) (Mediatech, Inc., Herndon, VA, USA) and the human melanoma cell 
line WM35 (ATCC) was maintained in Eagle's Minimum Essential Medium (MEM) 
(Mediatech, Inc.).  All cells were supplemented with 10% fetal bovine serum (FBS) 
(Gemini Biological Products, Calabasas, CA, USA), 100 units/mL penicillin and 100 
µg/mL streptomycin (Invitrogen, Carlsbad, CA, USA) and cultured in a humidified 
incubator with 5% CO2 at 37 °C.  For cell viability assays, 2.5 × 104 cells were plated 
onto 12-well tissue-culture treated plates (Fisher Scientific, Pittsburgh, PA, USA) using 
media supplemented with 1% FBS.  A-192621 (Abbott Laboratories, Abbott Park, IL, 
USA), BQ788 (EMD Chemicals Inc., San Diego, CA, USA) and/or BQ123 (EMD) were 
added 24 h after plating and viable cell number was assessed using the Live/Dead 
Viability/Cytotoxicity Kit for mammalian cells (Invitrogen) according to the 
manufacturer’s instructions.  Fluorescent intensity was measured on an FLx800 
multidetection microplate reader (BioTek, Winooski, VT, USA) and values represent the 
mean of a 25-point well scan. 
Cell proliferation and cell death.  LN-229 and SW1088 cells were plated at 5 × 
105 cells per 100 mm dish in DMEM with 1% FBS, and A-192621 was added 24 h later.  
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Cell cycle analysis was performed with a BrdU/propidium iodide double stain using the 
Absolute-S Cell Proliferation Kit (eBioscience, San Diego, CA, USA) according to the 
manufacturer’s instructions allowing 40 minutes to pulse-label cells with BrdU.  
Fluorescence was measured using the BD FACSCalibur System (Becton Dickinson, 
Franklin Lakes, NJ, USA).  The rate of cell proliferation was assessed using the 
CellTrace CFSE Cell Proliferation Kit (Invitrogen) according to the manufacturer’s 
instructions.  Cells were labeled with carboxyfluorescein diacetate succinimidyl ester 
(CFSE) at the time of plating and fluorescence intensity was analyzed at 9, 24, 48 and 72 
h after the addition of A-192621 using the BD FACSCalibur System.  Cell death was 
quantified by staining cells with propidium iodide (Invitrogen) following treatment with 
A-192621.  Fluorescence intensity was analyzed using the BD FACSCalibur System.  All 
FACS data was analyzed with FlowJo (Tree Star, Inc., Ashland, OR, USA).  Caspase 3/7 
activity was measured using EnzChek Caspase-3 Assay Kit #2 (Invitrogen) according to 
the manufacturer’s instructions and values adjusted for total cell number.  Fluorescence 
intensity was measured using the FLx800 multi-detection microplate reader. 
Microarray analysis.  LN-229 and SW1088 cells were treated with A-192621 for 
12 h and total RNA was prepared using the RNeasy Plus Mini Kit (Qiagen, Valencia, 
CA, USA).  The quality of the samples was checked using the RNA 6000 Nano LabChip 
kit (Agilent Technologies, Santa Clara, CA, USA).  RNA samples were then processed 
according to the Affymetrix Eukaryotic Sample and Array Processing protocol.  
Hybridization of the in vitro amplified RNA to Affymetrix Human Genome U133Plus 
2.0 chips (Affymetrix, Inc., Santa Clara, CA, USA), washing and scanning of the arrays 
were performed following standard Affymetrix protocols using a Hybridization Oven 
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640, a Fluidics Station 450, and a GeneChip® Scanner 3000 7G.  The raw data (*.cel 
files) from the Affymetrix hybridizations were processed and analyzed using Resolver 
(Rosetta Biosoftware, Seattle, WA, USA).   
Real-time reverse-transcription PCR.  Total RNA was prepared using the 
RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA).  The cDNA was prepared from 1 
µg total RNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied 
Science, Indianapolis, IN, USA) according to the manufacturers instructions.  
Primer/probe design was accomplished using the Universal ProbeLibrary (UPL) Assay 
Design Center (Roche Applied Science).  The primer sets (Integrated DNA Technologies, 
Coralville, IA, USA) were as follows: 5'-GGC AGA AGC TGA AAG GTC TC-3' and 5'-
CAT CGA AGC ACT GTC TCA GAG T-3' (DR5), 5'-GGA GAG CAG AAG ACC 
GAA AG-3' and 5'-AGT GAT CGT GCG CTG ACT C-3' (GADD45A), 5'-GCT TCT 
GGC AGA CCG AAC-3' and 5'-GTA GCC TGA TGG GGT GCT T-3' (GADD34), 5 '-
ACT GCG TCT TTG GCA TCA G-3' and 5'-GTA GCA GGC CAC TGT CTT GA-3' 
(Sestrin 2), 5'-AAG GCA CTG AGC GTA TCA TGT-3' and 5'-TGA AGA TAC ACT 
TCC TTC TTG AAC AC-3' (GADD153), 5'-TTC ATC CCG TTC AGA AGA CA-3' and 
5'-CCA ATG GCA AGC AGA AAT AGA-3' (ETRB) and 5'-TGA CCT TGA TTT ATT 
TTG CAT ACC-3' and 5'-CGA GCA AGA CGT TCA GTC CT-3' (HPRT).  The 
corresponding probes were UPL probe #63 (DR5), #65 (GADD45A), #28 (GADD34), 
#17 (Sestrin 2), #21 (GADD153), #83 (ETRB) and #73 (HPRT) (Roche Applied 
Science).  PCR was performed and analyzed on a LightCycler 480 System (Roche 
Applied Science) using LightCycler 480 Probes Master (Roche Applied Science).  The 
PCR was done under the following conditions: pre-incubation at 95 °C for 5 minutes, 45 
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cycles of amplification with melting at 95 °C for 8 seconds, annealing at 60 °C for 15 
seconds and extension at 72 °C for 2 seconds, and 1 cycle of cooling at 40 °C for 10 
seconds.  All gene expression was quantified relative to HPRT expression. 
Small interfering RNA (siRNA).  Following the reverse transfection protocol, 
Lipofectamine RNAiMAX (Invitrogen) was diluted in Opti-MEM I Medium (Invitrogen) 
and ON-TARGETplus SMARTpool ETRB siRNA or ON-TARGETplus siCONTROL 
non-targeting siRNA (Dharmacon, Lafayette, CO, USA) was diluted in Opti-MEM I 
Medium without serum.  These solutions were then combined and incubated together at 
room temperature for 10-20 minutes.  The siRNA duplex–Lipofectamine RNAiMAX 
complexes were then plated and overlaid with 2.5 × 104 cells per ml in media with 1% 
FBS.  Media was changed 4-6 h after plating and cells were treated as described above.  
ETRB gene expression was assessed by real-time PCR and was reduced by 70 - 93%.  
Statistical Analysis.  Values are expressed as mean ± SEM.  Statistical analysis 
was done using one-way ANOVA with Tukey posthoc unless otherwise noted. P < 0.05 
was considered statistically significant. 
 
Results 
Endothelin receptor B antagonist A-192621 reduces the number of viable glioma 
and melanoma cells in a dose- and time-dependent manner.  To test the effectiveness 
of A-192621 in reducing viable glioma cells we employed two human glioma cell lines, 
LN-229 and SW1088.  LN-229 was originally derived from a grade IV glioblastoma and 
SW1088 was derived from an anaplastic astrocytoma.  A-192621 was added at 
concentrations of 1, 25, 50, 75 or 100 µM to nonconfluent cells 24 h after plating and 
 107 
incubated for 24, 48 or 72 h.  Viable cells were identified by the capacity of their 
intracellular esterases to convert non-fluorescent calcein AM into green-fluorescent 
calcein.  This assay reveals a decrease in viable cell number with increasing A-192621 
concentration (Fig. 1A). This decrease in viable cell number is enhanced with longer 
incubation times (Fig. 1A).  In addition, A-192621 is effective in reducing viable cell 
number in the melanoma cell lines A375 and WM35 in a dose- and time-dependent 
manner (Fig. 1A).  This finding with melanoma cells is consistent with previously 
published data reporting that A-192621 inhibits melanoma growth in nude mice (13).  We 
also tested the ability of endothelin receptor B-specific antagonist BQ788 to reduce the 
number of viable cells in glioma cell lines LN-229 and SW1088. This agent causes a 
significant decrease in the number of viable LN-229 cells after 48 or 72 h of treatment 
but no significant change in SW1088 cell number (Fig. 1B).  BQ788 also reduces cell 
viability in both melanoma cell lines in a dose- and time-dependent manner (Fig. 1B).  
This result is consistent with previous findings in our laboratory (22).  To assess the 
involvement of ETRA in viability, cells were treated with BQ123, an endothelin receptor 
A-specific antagonist.  BQ123 was added to cells at 1, 25 50, 75 or 100 µM and 
incubated for 24, 48 or 72 h. No significant changes in cell viability were observed in any 
of the four cell lines, at any concentration or time point (Suppl. Fig. 1).  Thus, cross-
reaction of A-192621 and BQ788 with ETRA does not play a role in their effects on cell 
viability. 
 A-192621 decreases glioma cell proliferation and increases cell death.  To 
investigate how A-192621 reduces glioma cell numbers we assessed the rate of cell 
proliferation over time. The human glioma cell lines LN-229 and SW1088 were labeled 
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with carboxyfluorescein diacetate succinimidyl ester (CFSE).  This non-fluorescent 
reagent passively diffuses into cells where the acetate groups are cleaved by intracellular 
esterases, producing green-fluorescent carboxyfluorescein succinimidyl ester.  The 
succinimidyl ester groups react with intracellular amines and fluorescence intensity is 
exponentially diluted as cells divide. Fluorescence intensity was measured by FACS at 9, 
24, 48 and 72 h.  We tested two doses of A-192621, 10 nM, a concentration slightly 
above the IC50 that is calculated from radio-labeled ET-1 binding displacement studies 
(23), and 100 µM, a concentration that dramatically reduces the number of viable cells in 
both LN-229 and SW1088 (Fig. 1A).  We find that 100 µM, but not 10 nM, significantly 
reduces CFSE fluorescence dilution in both LN-229 and SW1088 cells at 24 h, and this 
effect is sustained through later time points, indicating that cells treated with A-192621 
are not undergoing as many cell divisions (Fig. 2A).  We also examined the cell cycle 
status of both LN-229 and SW1088 following A-192621 treatment using a 
BrdU/propidium iodide (PI) double stain.  Following treatment with A-192621, cultures 
were labeled with BrdU for 40 min to identify cells undergoing DNA synthesis and fixed 
immediately afterwards.  Cells were analyzed by FACS and BrdU intensity was plotted 
against DNA content.  In both LN-229 and SW1088 cells, 100 µM A-192621 
significantly increases the percentage of cells in the G2/M phase compared to vehicle, or 
to 10 nM treatment after 24 h (data not shown).  This accumulation of cells in the G2/M 
phase continues through 72 h and is coupled with a concomitant decrease in the G1/G0 
population (Fig. 2B), indicating that A-192621 induces a G2/M phase arrest.  In addition 
to effects on proliferation, we investigated whether A-192621 treatment also affects cell 
death, as measured by the percentage of total cells that stain positively with PI.  A-
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192621 significantly increases cell death at 48 in both LN-229 and SW1088 cells, and at 
72 h in SW1088 cells (Fig. 2C).  As a measure of apoptotic cell death, caspase 3/7 
activity is increased at 72 and 48 h in LN-229 and SW1088 cells, respectively (Fig 2D). 
 Genes associated with DNA damage are up-regulated following A-192621 
treatment.  In order to further understand the effects of A-192621, we assessed changes 
in gene expression by microarray analysis following a 12 h treatment of A-192621.  A 
striking finding is that A-192621 up-regulates several genes that are known to be induced 
by DNA damage (Table 1).  Growth arrest- and DNA damage-inducible (GADD) 45A is 
induced by environmental stressors such as methylmethane sulfonate, UV or gamma 
irradiation (24).  The subsequent expression of GADD45A, and other GADD45-like 
genes, activates the p38/JNK pathway and apoptosis.  GADD45A has also been 
implicated in inducing G2/M cell cycle arrest through its interaction with Cdc2 and 
cyclin B1 following genotoxic stress (25-28).  Two other members of the GADD family, 
GADD34 and GADD153, are also up-regulated by A-192621 treatment.  Like other 
members of this family, GADD34 and GADD153 are induced by stressful growth 
conditions and DNA damage.  Over-expression of GADD34 and GADD153, along with 
GADD45 and others, suppresses cell growth as measured by colony formation and 
induces apoptosis (29-32).  Sestrin 2 is one of three closely related genes in the sestrin 
family (33) and is closely linked to other GADD genes since sestrin 1, also known as 
PA26 (34), is a member of the GADD gene family.  Sestrin 2, also known as Hi95, is 
induced by hypoxia, oxidative stress and DNA damage (35). Over-expression of sestrin 2 
leads to apoptosis approximately 24 h following induction, and the cells are 
hypersensitive to further insult.  DR5 is one of the TRAIL receptors with a cytoplasmic 
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death domain that induces caspase-dependent apoptosis (36-38).  DR5 is induced by 
DNA damaging compounds in malignant gliomas, including LN-229 (39).  Taken 
together, this evidence suggests that A-192621 affects glioma viability by activating 
stress/DNA damage response pathways, which leads to cell cycle arrest and apoptosis. 
 A-192621 and BQ788 effects on cell viability are not mediated by endothelin 
receptor B.  The concentrations A-192621 and BQ788 required to reduce cell viability 
are well above their respective IC50s to displace ET-1 (23, 40).  Moreover, when we 
examined expression levels by real-time PCR, we could not detect ETRB in the SW1088 
cell line after 45 amplification cycles (Fig 3A).  These data led us to question the 
involvement of ETRB in the reduction of viable cell numbers by ETRB antagonists.  To 
address this question we reduced the expression level of ETRB 69-93%, using small 
interfering RNA (siRNA) (Fig 3B).  All cell lines were transfected with siRNAs targeting 
ETRB or a scrambled siRNA, and then treated 24 h later with 100 µM A-192621, BQ788 
or their respective vehicles.  The number of viable cells was assessed at 24, 48 or 72 h.  
Reduced ETRB expression in vehicle-treated cells did not affect cell viability.  Both A-
192621 and BQ788 decreased the number of viable cells equivalently in cells transfected 
with ETRB-targeting siRNA and scrambled siRNA at all time points (Fig. 3C, 24 and 48 
hours not shown). That ETRB knockdown does not abrogate A-192621- or BQ788-
mediated reduction in cell viability indicates that antagonism of this receptor is not 
important for the therapeutic effects of these two drugs. 
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Discussion 
We show here that both melanoma and glioma cell viability are sensitive to ETRB 
antagonists.  Both BQ788 and A-192621 decrease melanoma and glioma cell number in a 
dose- and time-dependent manner.  We find that A-192621 is more potent than BQ788, 
causing a greater decrease in viable cell numbers at lower concentrations and at earlier 
time points.  In fact, within the time frame tested, only A-192621 was able to reduce the 
viable cell number in the astrocytoma line SW1088. 
A-192621 is more attractive as a therapeutic agent since it is orally bioavailable, 
and considering that it is also more potent than BQ788, we investigated how it reduces 
glioma cell number in greater detail.  CFSE labeling indicates that A-192621 inhibits 
mitosis.  Using cell cycle analysis, treatment of LN-229 and SW1088 with A-192621 
increases in the percentage of cells with G2/M DNA content over time.  This is coupled 
with a concomitant decrease in the percentage of cells with G0/G1 DNA content, 
indicating an arrest in the G2/M phase of the cell cycle, which likely accounts for the 
reduction in cell divisions seen with CFSE labeling.  We also find that A-192621 
treatment induces apoptotic cell death.  Reduction in viable cell number is therefore a 
consequence of both decreased mitogenesis and increased apoptosis.  To our knowledge, 
this is the first evidence of ETRB antagonist-induced G2/M cell cycle arrest. 
To further elucidate the actions of A-192621, we analyzed changes in gene 
expression using microarray technology.  Notably, after 12 h of A-192621 treatment, 
there are significant increases in the expression of several genes known to be up-
regulated following DNA damage.  These genes include GADD153, GADD45A, 
GADD34, Sestrin 2 and DR5.  Up-regulation of these genes may account for the G2/M 
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arrest and the apoptosis we see at later time points.  This is the first evidence linking 
ETRB antagonist treatment to enhanced expression of DNA damage-associated genes. 
We also present evidence that the reduction in both melanoma and glioma cell 
viability by A-192621 and BQ788 does not require the expression of ETRB.  This 
conclusion is supported by three types of data.  (1) The concentration of ETRB 
antagonists required to reduce cell number is approximately 20,000-fold above the 
reported IC50s for A-192621 and BQ788 to displace ET-1.  (2) At these high doses, the 
antagonists reduce cell viability in the glioma cell line SW1088 despite the absence of 
detectable ETRB expression. (3) Reduction of ETRB expression by siRNA has no effect 
on the ability of either antagonist to reduce cell number. 
We have demonstrated that ETRB antagonists are effective agents against 
melanoma and glioma cell growth in vitro.  To date, mechanisms of ETRB antagonist 
action in cancer treatment have focused on blocking ET-1 induced pathways.  Although 
determining the precise mechanism by which ETRB antagonists reduce cell number in 
these cancers is beyond the scope of this study, the data presented here indicate that 
ETRB antagonists function independently from direct ETRB antagonism to mediate their 
effects on cancer progression.   
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Tables 
Table 1.  Treatment of glioma and melanoma cell lines with 100 µM A-192621 up-
regulates DNA damage-related genes. Genes were identified by microarray analysis and 
real-time RT-PCR was used to quantify the fold-increase in expression over vehicle-
treated controls.  
 
Genes Cell Lines 
 LN-229 SW1088 A375 WM35 
GADD153 28 12 10 66 
GADD45A 23 5 9 8 
GADD34 16 3 21 6 
Sestrin 2 15 18 19 12 
DR5 12 4 10 5 
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Figure Legends 
Figure 1. Endothelin receptor B antagonists reduce the number of viable cells in a dose- 
and time-dependent manner.  (A) A-192621 significantly reduces the number of viable 
cells in both glioma (LN-229 and SW1088) and melanoma (A375 and WM35) cell lines 
at 24, 48 and 72 h of treatment.  (B) BQ788 significantly reduces the number of viable 
cells in melanoma at 48 and 72 h of treatment.  Values are expressed as the mean of three 
replicates ± SEM. # P < 0.05, ♠ P < 0.01, ♣ P < 0.001 compared with vehicle-treated 
controls. Colors correspond to the cell line. 
 
Figure 2. The endothelin B receptor antagonist A-192621 decreases glioma cell 
proliferation and increases cell death. (A) A-192621 suppresses cell proliferation.  LN-
229 and SW1088 cells were stained with CFSE and analyzed by FACS at 9, 24, 48 and 
72 h after addition of A-192621.  The exponential dilution of CFSE was converted to the 
number of cell divisions. (B) A high concentration of A-192621 (100µM) induces G2/M 
cell cycle arrest in both LN-229 and SW1088 cells by 72 h. Cells were pulsed-labeled 
with BrdU, stained with propidium iodide and analyzed by FACS. (C) A-192621 induces 
cell death at 48 and 72 h.  LN-229 and SW1088 cells were stained with propidium iodide 
following treatment with A-192621 and analyzed by FACS.  (D) A-192621 induces 
apoptosis by 72 and 48 h in LN-229 and SW1088 cell lines respectively.  Caspase 3/7 
activity was adjusted for total cell number. Values are expressed as means of three 
replicates ± SEM. # P < 0.05, ♠ P < 0.01, ♣ P < 0.001 compared with vehicle-treated 
controls. 
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Figure 3.  Reduction of ETRB expression levels does not alter the effect of ETRB 
antagonists on viable cell number.  (A) ETRB mRNA in untreated cell lines. ETRB 
mRNA was not detected in the SW1088 line.  (B) Following transfection, reduction in 
ETRB mRNA was assessed by real-time RT-PCR.  Reduction in ETRB expression is 
displayed as a percentage relative to ETRB mRNA in cells transfected with scrambled 
siRNA.  (C) Cells were transfected with either scrambled siRNA or ETRB siRNA and 
then treated with either 100 µM A-192621 or 100 µM BQ788 for 72 h.  Values are 
expressed as a mean of three replicates ± SEM. Significance was determined by a paired 
t-test # P < 0.05, ♠ P < 0.01, ♣ P < 0.001. 
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Supplementary Data 
Supplemental Figure 1.  The endothelin receptor A-specific antagonist BQ123 does not 
affect viable cell number in glioma or melanoma cell lines.  Cells were treated with 
BQ123 for 72 h. Values are expressed as means of three replicates ± SEM compared with 
vehicle-treated controls. 
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Supplementary Figure 1 
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Chapter VI  
Comments and Future Considerations 
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Comments 
When I began my investigation into the effects of endothelin receptor antagonists 
on cancer progression I was assessing cell viability using the TACS MTT (3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) Cell Proliferation and Viability 
Assay (R&D Systems, Inc., Minneapolis, MN, USA).  In short, the MTT compound is 
added to cell culture wells and mitochondrial reductase enzymes reduce the compound to 
insoluble purple formazan dye crystals.  Detergent is then added to solubilize the crystals 
and absorbance is read at 570 nm.  The intensity of absorbance is proportional to the 
number of viable cells.  This assay, and the very similar MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), is commonly used 
to assess cell viability, as they are rapid, relatively inexpensive and high-throughput.  I 
found, however, that the results of the MTT assay did not correlate well with my other 
assays such as the CFSE labeling, cell cycle analysis and cell death quantification.  This 
led me to reassess the viable cell numbers using the Live/Dead Viability/Cytotoxicity Kit 
for mammalian cells (Invitrogen, Carlsbad, CA, USA).  This assay relies on intracellular 
esterases to cleave non-fluorescent calcein AM into green-fluorescent calcein.  
Fluorescent intensity is proportional to the number of viable cells.  When directly 
compared, the two assays yield strikingly different results (Fig. 1).  The MTT assay (Fig. 
1A) is not as sensitive as the Live/Dead Assay (Fig. 1B).   
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Figure 1.  MTT viability assay masks effects of A-192621. (A) MTT viability assay measuring A-192621-
induced reduction of cell viability at 48 hours.  The lack of an observed A-192621 effect on the SW1088 
line does not correlate with other assays. (B) Live/Dead viability assay measuring A-192621-induced 
reduction of cell viability at 48 hours.  SW1088 and LN-229 cell lines have a similar response to A-
192621. 
 
The Live/Dead results indicate that LN-229 and SW1088 respond similarly to A-
192621 while the MTT assay indicates that cell viability in SW1088 does is not affected 
by A-192621.  The Live/Dead data correlate with the CFSE labeling, cell cycle analysis 
and cell death assays that also demonstrated a similar response in LN-229 and SW1088 
cell lines following addition of A-192621.  One explanation for the discrepancy could be 
that mitochondrial reductase activity does not accurately represent cell number.  Another, 
more likely, explanation in this case is that cell density may have influenced the outcome 
of the viability assays.  The MTT assays I conducted were cultured in 96-well plates as 
recommended by the manufacturer.  Cells tend to clump in 96-well plates creating areas 
of higher density.  In areas of higher density, growth factors secreted by cells would be in 
higher concentration and possibly be better able to counteract the effects of the 
endothelin B receptor antagonists.  To avoid this occurrence, the Live/Dead experiments 
were conducted in 12-well plates.  The smaller surface tension to surface area ratio in a 
12-well plate permits an even cell distribution across the well thus eliminating any 
increased paracrine activity.  To follow up on the effectiveness of the MTT assay it 
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should be scaled up to a 12-well format and compared to other assays.  Currently, I 
recommend that investigators avoid using the MTT assay in the 96-well format and all 
results should be confirmed by other means.  This is particularly important since in the 
literature claims of specificity of drug action have been made using this assay and it is 
clear from my work that effects may have been overlooked. 
 
Future Considerations 
 For researchers with an interest in continuing the investigations described in the 
preceding chapter, I would recommend that the CFSE labeling, cell cycle analysis and 
cell death assays be repeated with the siRNA knockdown of ETRB.  I hypothesize that 
that the results will not differ compared to a non-targeting siRNA control, confirming my 
findings that indicate A-192621 reduces cell numbers independently of ETRB 
expression.  Another experiment to confirm that the cytotoxic effects of A-192621 are not 
mediated via ETRB would be an agonist-antagonist competition assay.  Increasing 
concentrations of an ETRB-specific agonist, such as sarafotoxin 6c or IRL-1620, could 
be added to compete with the antagonist for ETRB binding sites.  The effect of A-192621 
on cell viability should not change in the presence of high concentrations of a competitive 
agonist, which will saturate the available ETRB binding sites.  By their very nature 
ETRB agonists are mitogenic (Shichiri et al., 1991); a complicating factor in these 
proposed experiments.  Therefore, the necessary control for assessing the effects of A-
192621 on cell viability of A-192621/agonist co-incubated cells will be agonist alone 
treated cultures.  The more refined approach would be to use a neutralizing antibody to 
occupy the ETRB binding site but such a molecule is not available at present. 
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 Following the confirmation that A-192621 reduces cell viability independently of 
ETRB, there are two important in vivo experiments I would recommend.  1) Assess the 
effect of A-192621 in a xenograft model of glioma in nude mice.  A-192621 should be 
administered intravenously in one group of animals and orally in another to determine the 
most effective method of delivery.  It has already been demonstrated that therapeutic 
doses of A-192621 are well tolerated in mice with no signs of acute or delayed toxicity 
(Bagnato et al., 2004).  2) Confirm that A-192621 reduces tumor viability independently 
of ETRB in vivo.  First, an in vivo tumor model that responds to A-192621 is needed.  
This could be the aforementioned experiment or the melanoma model described by 
Bagnato and colleagues (Bagnato et al., 2004).  Tumor cells should be stably transfected 
with a lentiviral shRNA vector targeting ETRB.  Cells showing the greatest reduction in 
ETRB expression should be selected, cloned and injected into animals.  Controls should 
include ETRB-null tumors without A-192621 treatment and animals injected with wild-
type tumors with and without A-192621 treatment.  A-192621 dosage should follow the 
same course found to be effective in wild-type tumors in proposed experiment 1.  
Assuming that A-192621 reduces tumor viability independently of ETRB binding one 
will not expect to record a difference in its effect on wild-type and ETRB-null tumor 
progression. 
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